BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwarz KB, Rosensweig J, Sharma S, Jones L, Durant M, Potter C, Narkewicz MR. Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J Pediatr Gastroenterol Nutr 2003;37:187-91. [PMID: 12883307 DOI: 10.1097/00005176-200308000-00019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Philippé J, De Logi E, Baele G. Comparison of Five Different Citrated Tubes and Their in Vitro Effects on Platelet Activation. Clinical Chemistry 2004;50:656-8. [DOI: 10.1373/clinchem.2003.028704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
2 Wu H, Yang J, Su EM, Li L, Zhao C, Yang X, Gao Z, Pan M, Sun P, Sun W, Jiang Y, Su X. Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice. PLoS One 2014;9:e93003. [PMID: 24671173 DOI: 10.1371/journal.pone.0093003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Brazova J, Sismova K, Vavrova V, Bartosova J, Macek M Jr, Lauschman H, Sediva A. Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin Immunol 2006;121:350-7. [PMID: 17052957 DOI: 10.1016/j.clim.2006.08.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
4 Murugavel S, Bugyei-Twum A, Matkar PN, Al-Mubarak H, Chen HH, Adam M, Jain S, Narang T, Abdin RM, Qadura M, Connelly KA, Leong-Poi H, Singh KK. Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching. Front Pharmacol 2018;9:737. [PMID: 30050438 DOI: 10.3389/fphar.2018.00737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
5 Karnsakul W, Wasuwanich P, Ingviya T, Vasilescu A, Carson KA, Mogayzel PJ, Schwarz KB. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease.J Cyst Fibros. 2020;19:546-552. [PMID: 32482593 DOI: 10.1016/j.jcf.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Maloney JP, Narasimhan J, Biller J. Decreased TGF-β1 and VEGF Release in Cystic Fibrosis Platelets: Further Evidence for Platelet Defects in Cystic Fibrosis. Lung 2016;194:791-8. [PMID: 27423781 DOI: 10.1007/s00408-016-9925-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
7 Sagwal S, Chauhan A, Kaur J, Prasad R, Singh M, Singh M. Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation. Lung 2020;198:377-83. [PMID: 31919585 DOI: 10.1007/s00408-020-00320-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Srivastava M, Eidelman O, Jozwik C, Paweletz C, Huang W, Zeitlin PL, Pollard HB. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Molecular Genetics and Metabolism 2006;87:303-10. [DOI: 10.1016/j.ymgme.2005.10.021] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
9 Harris WT, Muhlebach MS, Oster RA, Knowles MR, Noah TL. Transforming growth factor-beta(1) in bronchoalveolar lavage fluid from children with cystic fibrosis. Pediatr Pulmonol 2009;44:1057-64. [PMID: 19830844 DOI: 10.1002/ppul.21079] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lindberg U, Svensson L, Hellmark T, Segelmark M, Shannon O. Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status. Thrombosis Research 2018;162:32-7. [DOI: 10.1016/j.thromres.2017.12.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Büscher R, Grasemann H. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road? Naunyn Schmiedebergs Arch Pharmacol 2006;374:65-77. [PMID: 17033796 DOI: 10.1007/s00210-006-0101-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tobolowsky FA, Wada N, Martinez-Maza O, Magpantay L, Koletar SL, Palella FJ Jr, Brown TT, Lake JE. Brief report: Circulating markers of fibrosis are associated with immune reconstitution status in HIV-infected men. PLoS One 2018;13:e0191606. [PMID: 29381717 DOI: 10.1371/journal.pone.0191606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Affandi AJ, Carvalheiro T, Ottria A, de Haan JJ, Brans MAD, Brandt MM, Tieland RG, Lopes AP, Fernández BM, Bekker CPJ, van der Linden M, Zimmermann M, Giovannone B, Wichers CGK, Garcia S, de Kok M, Stifano G, Xu YJ, Kowalska MA, Waasdorp M, Cheng C, Gibbs S, de Jager SCA, van Roon JAG, Radstake TRDJ, Marut W. CXCL4 drives fibrosis by promoting several key cellular and molecular processes. Cell Rep 2022;38:110189. [PMID: 34986347 DOI: 10.1016/j.celrep.2021.110189] [Reference Citation Analysis]
14 Mak JC, Ho SP, Leung RY, Ho PL, Ooi C, Tipoe GL, Yan C, Ip MS, Lam WK, Tsang KW. Elevated levels of transforming growth factor-β1 in serum of patients with stable bronchiectasis. Respiratory Medicine 2005;99:1223-8. [DOI: 10.1016/j.rmed.2005.02.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
15 O'Sullivan BP, Michelson AD. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med 2006;173:483-90. [PMID: 16339920 DOI: 10.1164/rccm.200508-1243PP] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
16 Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004;6:231-9. [DOI: 10.1007/s11894-004-0013-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
17 O'Sullivan BP, Linden MD, Frelinger AL 3rd, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD. Platelet activation in cystic fibrosis. Blood 2005;105:4635-41. [PMID: 15705796 DOI: 10.1182/blood-2004-06-2098] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
18 Guillot L, Beucher J, Tabary O, Le Rouzic P, Clement A, Corvol H. Lung disease modifier genes in cystic fibrosis. Int J Biochem Cell Biol 2014;52:83-93. [PMID: 24569122 DOI: 10.1016/j.biocel.2014.02.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
19 Eickmeier O, Boom Lv, Schreiner F, Lentze MJ, NGampolo D, Schubert R, Zielen S, Schmitt-Grohé S. Transforming growth factor β1 genotypes in relation to TGFβ1, interleukin-8, and tumor necrosis factor alpha in induced sputum and blood in cystic fibrosis. Mediators Inflamm 2013;2013:913135. [PMID: 24062613 DOI: 10.1155/2013/913135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]